# Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

> **NCT05981040** · PHASE2 · COMPLETED · sponsor: **Zydus Lifesciences Limited** · enrollment: 24 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** ZYIL1 capsules 25 mg and 50 mg Placebo
- **DRUG:** ZYIL1 capsules 50 mg and 25 mg Placebo
- **DRUG:** ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg
- **DRUG:** Matching placebo 25 mg and Matching placebo 50 mg

## Key facts

- **NCT ID:** NCT05981040
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-09
- **Primary completion:** 2024-06-26
- **Final completion:** 2024-06-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05981040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05981040, "Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05981040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*